Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Remy Sukhija leaving Madrigal as CCO

Plus: Editas hires Caren Deardorf as chief commercial and strategy officer, and updates from ProFound and hC

September 25, 2023 11:48 PM UTC

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) said Remy Sukhija is departing as chief commercial officer to pursue other opportunities. His departure comes two weeks after FDA granted Madrigal’s resmetirom priority review for non-alcoholic steatohepatitis with liver fibrosis; the PDUFA date is March 14. Sukhija joined the company in April 2020 from Otsuka Pharmaceutical Co. Ltd., where he was SVP, U.S. commercial.

Genome editing company Editas Medicine Inc. (NASDAQ:EDIT) hired Caren Deardorf as its first chief commercial and strategy officer. Deardorf, a 15-year veteran of Biogen Inc. (NASDAQ:BIIB), was CCO at Magenta Therapeutics Inc. and Ohana Biosciences. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article